A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

Maya Koren-Michowitz; Avichai Shimoni; Asaf Vivante; Luba Trakhtenbrot; Gideon Rechavi; Ninette Amariglio; Ron Loewenthal; Arnon Nagler; Yoram Cohen

doi:10.1016/j.leukres.2007.07.003

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

Maya Koren-Michowitz, Avichai Shimoni, Asaf Vivante, Luba Trakhtenbrot, Gideon Rechavi, Ninette Amariglio, Ron Loewenthal, Arnon Nagler, Yoram Cohen

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16-98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor-recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.

Original language	English
Pages (from-to)	421-427
Number of pages	7
Journal	Leukemia Research
Volume	32
Issue number	3
DOIs	https://doi.org/10.1016/j.leukres.2007.07.003
State	Published - Mar 2008
Externally published	Yes

Keywords

Allo SCT
JAK2 V617F
MALDI-TOF
Myeloproliferative disorders

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2007.07.003

Cite this

Koren-Michowitz, M., Shimoni, A., Vivante, A., Trakhtenbrot, L., Rechavi, G., Amariglio, N., Loewenthal, R., Nagler, A., & Cohen, Y. (2008). A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leukemia Research, 32(3), 421-427. https://doi.org/10.1016/j.leukres.2007.07.003

@article{c9d8c54c6569415ca1fd14bf9f3b106a,

title = "A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)",

abstract = "JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16-98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor-recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.",

keywords = "Allo SCT, JAK2 V617F, MALDI-TOF, Myeloproliferative disorders",

author = "Maya Koren-Michowitz and Avichai Shimoni and Asaf Vivante and Luba Trakhtenbrot and Gideon Rechavi and Ninette Amariglio and Ron Loewenthal and Arnon Nagler and Yoram Cohen",

year = "2008",

month = mar,

doi = "10.1016/j.leukres.2007.07.003",

language = "אנגלית",

volume = "32",

pages = "421--427",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "3",

}

Koren-Michowitz, M, Shimoni, A, Vivante, A, Trakhtenbrot, L, Rechavi, G, Amariglio, N, Loewenthal, R, Nagler, A & Cohen, Y 2008, 'A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)', Leukemia Research, vol. 32, no. 3, pp. 421-427. https://doi.org/10.1016/j.leukres.2007.07.003

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). / Koren-Michowitz, Maya; Shimoni, Avichai; Vivante, Asaf et al.
In: Leukemia Research, Vol. 32, No. 3, 03.2008, p. 421-427.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

AU - Koren-Michowitz, Maya

AU - Shimoni, Avichai

AU - Vivante, Asaf

AU - Trakhtenbrot, Luba

AU - Rechavi, Gideon

AU - Amariglio, Ninette

AU - Loewenthal, Ron

AU - Nagler, Arnon

AU - Cohen, Yoram

PY - 2008/3

Y1 - 2008/3

N2 - JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16-98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor-recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.

AB - JAK2 V617F mutation is found in a high proportion of MPD patients. We developed a quantitative assay for the detection of the JAK2 mutation and demonstrated its clinical utility in MPD patients who underwent SCT. Sixty percent of the patients were JAK2 V617F positive prior to the SCT (mean mutation levels 74%, range 16-98%). After the procedure, the mutation levels progressively decreased and were in correlation with the donor-recipient chimerism status (r = 0.97, p < 0.001). At a median follow up of 16 months (range 2-58), 9/15 patients are alive and in CR. The levels of the JAK2 V617F mutation reached 0% in all surviving patients.

KW - Allo SCT

KW - JAK2 V617F

KW - MALDI-TOF

KW - Myeloproliferative disorders

UR - http://www.scopus.com/inward/record.url?scp=39749192828&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2007.07.003

DO - 10.1016/j.leukres.2007.07.003

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 17698191

AN - SCOPUS:39749192828

SN - 0145-2126

VL - 32

SP - 421

EP - 427

JO - Leukemia Research

JF - Leukemia Research

IS - 3

ER -

A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD)

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this